RegeneRx Biopharmaceuticals Inc. (“RegeneRx” or the “Company”) (OTCQB:RGRX) is a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. We have formulated Tß4 into three distinct product candidates in clinical development:
Company profile
Ticker
RGRXD, RGRXD
Exchange
Website
CEO
J. J. Finkelstein
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
ALPHA 1 BIOMEDICALS INC, ALPHA 1 BIOMEDICALS INC /DE/
SEC CIK
Corporate docs
IRS number
521253406
RGRXD stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
14 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
7 Aug 23
DEF 14A
Definitive proxy
11 Jul 23
8-K
Entry into a Material Definitive Agreement
10 Jul 23
PRE 14A
Preliminary proxy
23 Jun 23
8-K
Entry into a Material Definitive Agreement
20 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
11 Apr 23
NT 10-K
Notice of late annual filing
3 Apr 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 101.56 k | 101.56 k | 101.56 k | 101.56 k | 101.56 k | 101.56 k |
| Cash burn (monthly) | 63.11 k | 68.65 k | 128.40 k | 140.72 k | 63.11 k | 68.65 k |
| Cash used (since last report) | 512.86 k | 557.83 k | 1.04 mm | 1.14 mm | 512.86 k | 557.83 k |
| Cash remaining | -411.30 k | -456.28 k | -941.86 k | -1.04 mm | -411.30 k | -456.28 k |
| Runway (months of cash) | -6.5 | -6.6 | -7.3 | -7.4 | -6.5 | -6.6 |
Institutional ownership, Q2 2023
34.2% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 2 |
| Opened positions | 1 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 14.23 mm |
| Total shares | 51.53 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Essetifin SPA | 51.52 mm | $13.96 mm |
| Williams Jones Wealth Management | 10.00 k | $266.00 k |